Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment-Reference-Cited by-同舟云学术

Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment

Published:2022-07-03 Issue:15 Volume:13 Page:2170-2179
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Kim Jehun¹^ORCID,Kim Taeyun²^ORCID,Jang Tae Won¹,Kang Hee³,Kim Mi Hyun⁴,Yoon Seong Hoon⁵,Son Choon‐Hee⁶,Lee Hyun‐Kyung⁷,Kim Hyun‐Kuk⁸,Lee Shin Yup⁹^ORCID,Shin Kyeong Choel¹⁰,Han Ji‐Yeon¹¹,Kang Eun‐Ju¹²

Affiliation:

1. Division of Pulmonology, Department of Internal Medicine Kosin University College of Medicine, Kosin University Gospel Hospital Busan South Korea

2. Department of Internal Medicine The Armed Forces Goyang Hospital Goyang‐si South Korea

3. Department of Radiology Kosin University College of Medicine, Kosin University Gospel Hospital Busan South Korea

4. Division of Pulmonology, Department of Internal Medicine Pusan National University Hospital Pusan South Korea

5. Division of Pulmonology, Department of Internal Medicine Pusan National University Yangsan Hospital Yangsan South Korea

6. Division of Pulmonology, Department of Internal Medicine Gwanghye General Hospital Pusan South Korea

7. Division of Pulmonology, Department of Internal Medicine Inje University Busan Paik Hospital Busan South Korea

8. Division of Pulmonology, Department of Internal Medicine Inje University Haeundae Paik Hospital Busan South Korea

9. Division of Pulmonology, Department of Internal Medicine Kyungpook National University Chilgok Hospital Daegu South Korea

10. Division of Pulmonology, Department of Internal Medicine Yeungnam University Hospital Daegu South Korea

11. Department of Radiology Inje University Busan Paik Hospital Busan South Korea

12. Department of Radiology Dong‐A University College of Medicine Busan South Korea

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14539

Reference33 articles.

1. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

2. CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC

3. Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

4. Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

5. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation;Frontiers in Immunology;2023-11-01

2. Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer;Frontiers in Immunology;2023-05-22

3. Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer;The Korean Journal of Internal Medicine;2023-03-01